Naya Biosciences Inc (NAYA)

$1.86 -0.24 (-11.43%)
Market Cap 1.47M
Revenue (ttm) 3.02M
Net Income (ttm) -8.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -265.89%
Debt to Equity Ratio -56.50
Volume 20,550
Avg Vol 24,319
Day's Range N/A - N/A
Shares Out 666,000.00
Stochastic %K 20%
Beta 2.03
Analysts Strong Sell
Price Target $24.01

Latest News on NAYA

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

Mar 13, 2025, 4:30 PM EDT - 21 days ago

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

Feb 25, 2025, 8:00 AM EST - 5 weeks ago

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

NAYA Biosciences Announces Nomination of New Board Members

Feb 19, 2025, 9:15 AM EST - 6 weeks ago

NAYA Biosciences Announces Nomination of New Board Members

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

Oct 24, 2024, 9:00 AM EDT - 5 months ago

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

Oct 21, 2024, 9:00 AM EDT - 5 months ago

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

Oct 14, 2024, 9:18 AM EDT - 6 months ago

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

INVO Reports Record First Quarter 2024 Financial Results

May 15, 2024, 4:15 PM EDT - 11 months ago

INVO Reports Record First Quarter 2024 Financial Results

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

Apr 16, 2024, 4:59 PM EDT - 1 year ago

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

Dec 11, 2023, 8:00 AM EST - 1 year ago

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Dec 6, 2023, 9:00 AM EST - 1 year ago

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Nov 28, 2023, 9:00 AM EST - 1 year ago

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

INVO Reports Record Third Quarter 2023 Financial Results

Nov 13, 2023, 4:01 PM EST - 1 year ago

INVO Reports Record Third Quarter 2023 Financial Results

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

Nov 10, 2023, 9:00 AM EST - 1 year ago

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants

Nov 9, 2023, 4:40 PM EST - 1 year ago

INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants

INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO

Oct 24, 2023, 8:37 PM EDT - 1 year ago

INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

Oct 23, 2023, 7:30 AM EDT - 1 year ago

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 11, 2023, 9:00 AM EDT - 1 year ago

INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS

Sep 29, 2023, 4:05 PM EDT - 1 year ago

INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS

INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET

Sep 28, 2023, 12:30 PM EDT - 1 year ago

INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET

INVO Bioscience, Inc. (INVO) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 10:50 PM EDT - 1 year ago

INVO Bioscience, Inc. (INVO) Q2 2023 Earnings Call Transcript

INVO Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:05 PM EDT - 1 year ago

INVO Reports Second Quarter 2023 Financial Results

INVO Closes Acquisition of Wisconsin Fertility Institute

Aug 11, 2023, 8:00 AM EDT - 1 year ago

INVO Closes Acquisition of Wisconsin Fertility Institute

INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Aug 9, 2023, 4:15 PM EDT - 1 year ago

INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

INVO Bioscience Announces Closing of $4.5 Million Public Offering

Aug 8, 2023, 1:55 PM EDT - 1 year ago

INVO Bioscience Announces Closing of $4.5 Million Public Offering

INVO Bioscience Announces Pricing of $4.5 Million Public Offering

Aug 4, 2023, 9:00 AM EDT - 1 year ago

INVO Bioscience Announces Pricing of $4.5 Million Public Offering

INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value

Aug 3, 2023, 8:00 AM EDT - 1 year ago

INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value

INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023

Jul 27, 2023, 9:27 AM EDT - 1 year ago

INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023

INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device

Jun 27, 2023, 9:00 AM EDT - 1 year ago

INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device

INVO Bioscience, Inc. (INVO) Q1 2023 Earnings Call Transcript

May 15, 2023, 8:05 PM EDT - 2 years ago

INVO Bioscience, Inc. (INVO) Q1 2023 Earnings Call Transcript

INVO Reports First Quarter 2023 Financial Results

May 15, 2023, 4:05 PM EDT - 2 years ago

INVO Reports First Quarter 2023 Financial Results

INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

May 8, 2023, 4:15 PM EDT - 2 years ago

INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

INVO Bioscience, Inc. (INVO) Q4 2022 Earnings Call Transcript

Apr 17, 2023, 7:01 PM EDT - 2 years ago

INVO Bioscience, Inc. (INVO) Q4 2022 Earnings Call Transcript

INVO Reports Fourth Quarter and Full Year 2022 Financial Results

Apr 17, 2023, 4:05 PM EDT - 2 years ago

INVO Reports Fourth Quarter and Full Year 2022 Financial Results

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023

Apr 11, 2023, 5:30 PM EDT - 2 years ago

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek

Apr 5, 2023, 9:00 AM EDT - 2 years ago

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek

INVO Provides Preliminary Update on FY2022 Financial Results

Mar 30, 2023, 5:25 PM EDT - 2 years ago

INVO Provides Preliminary Update on FY2022 Financial Results

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

Mar 27, 2023, 5:06 PM EDT - 2 years ago

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

Mar 24, 2023, 8:00 AM EDT - 2 years ago

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

Mar 20, 2023, 9:00 AM EDT - 2 years ago

INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

INVO Bioscience Enters Distribution Agreement for Taiwan

Jan 5, 2023, 9:00 AM EST - 2 years ago

INVO Bioscience Enters Distribution Agreement for Taiwan

INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center

Jan 3, 2023, 9:00 AM EST - 2 years ago

INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center

First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

Nov 30, 2022, 9:30 AM EST - 2 years ago

First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

INVO Bioscience, Inc. (INVO) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 9:18 PM EST - 2 years ago

INVO Bioscience, Inc. (INVO) Q3 2022 Earnings Call Transcript

INVO Bioscience Reports Third Quarter 2022 Financial Results

Nov 14, 2022, 4:05 PM EST - 2 years ago

INVO Bioscience Reports Third Quarter 2022 Financial Results

INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Nov 10, 2022, 4:15 PM EST - 2 years ago

INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

Nov 1, 2022, 9:00 AM EDT - 2 years ago

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

Oct 21, 2022, 9:00 AM EDT - 2 years ago

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

Oct 17, 2022, 9:00 AM EDT - 2 years ago

INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo